IPO registrations (S-1, F-1) · Registrants
Immunocore Holdings plc
- SEC CIK
- 1671927 · filings on EDGAR ↗
- Former names
- Immunocore Ltd (2016–2021)
- Registration
- Form F-1, first filed 2021-01-15, last 2021-02-03; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-02-08; declared effective 2021-02-04
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- X0
- Business address
- 90 PARK DRIVE, MILTON PARK, ABINGDON, Oxfordshire, X0 OX14 4RY
- Ticker
- IMCR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Immunocore Holdings plc on the corporate pages
Offering terms
- Proposed price range
- $23.00–$25.00 per ADS (F-1/A filed 2021-02-03)
- Final price
- $26.00 per ADS, above the range (424B4 filed 2021-02-08, an initial public offering)
- Shares sold
- 9,935,896
- Gross proceeds
- $258,333,296 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol IMCR
- Lead underwriters
- Goldman Sachs (3,725,961 shares); J.P. Morgan (3,725,961 shares); Jefferies (2,483,974 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Immunocore Holdings plc EXACT (CIK (EXACT))
- SEC filer: Immunocore Holdings plc EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-01-15 | F-1 | F-1 (foreign registration) | Immunocore Ltd | 0001140361-21-001312 ↗ |
| 2021-02-01 | F-1/A | F-1/A (amendment) | Immunocore Ltd | 0001140361-21-002787 ↗ |
| 2021-02-03 | F-1/A | F-1/A (amendment) | Immunocore Holdings plc | 0001140361-21-003273 ↗ |
| 2021-02-04 | F-1MEF | F-1MEF (added securities) | Immunocore Holdings plc | 0001140361-21-003455 ↗ |
| 2021-02-04 | EFFECT | EFFECT (declared effective) | Immunocore Holdings plc | 9999999995-21-000445 ↗ |
| 2021-02-04 | EFFECT | EFFECT (declared effective) | Immunocore Holdings plc | 9999999995-21-000461 ↗ |
| 2021-02-08 | 424B4 | 424B4 (final prospectus) | Immunocore Holdings plc | 0001140361-21-003664 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | F-1/A | registration statement | $23.00–$25.00 | $24.00 | 8,333,333 | $199,999,992 | Nasdaq IMCR | 3 | primary document; range, price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2021-02-08 | 424B4 | final prospectus | $26.00 | 9,935,896 | $258,333,296 | Nasdaq IMCR | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bell John Irving | Director | 4 | 2024–2026 | ||
| Berman David M | Officer | Head of R&D; HEAD OF R&D | 12 | 2024–2026 | |
| Coy Travis Alan | Director; Officer | Chief Financial Officer | 3 | 2024–2026 | |
| Di Donato Brian | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 2 | 2024 | |
| GOLL JOHN | Officer | SVP, Finance & CAO; SVP, FINANCE & CAO | 4 | 2024–2026 | |
| Herbst Roy Steven | Director | 4 | 2024–2026 | ||
| Jallal Bahija | Director,Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 4 | 2024–2026 | |
| Kaul Siddharth | Director | 4 | 2024–2026 | ||
| PEREZ ROBERT J | Director | 1 | 2024 | ||
| Peterson Kristine | Director | 4 | 2024–2026 | ||
| Ratcliffe Peter John | Director | 4 | 2024–2026 | ||
| St Leger Tina Amber | Officer | Chief HR Officer; CHIEF HR OFFICER | 6 | 2024–2026 | |
| 667, L.P. | Director | 4 | 2024–2025 | ||
| Baker Bros. Advisors (GP) LLC | Director | 4 | 2024–2025 | ||
| BAKER BROS. ADVISORS LP | Director | 4 | 2024–2025 | ||
| Baker Brothers Life Sciences LP | Director | 4 | 2024–2025 | ||
| BAKER FELIX | Director | 4 | 2024–2025 | ||
| BAKER JULIAN | Director | 4 | 2024–2025 | ||
| KRISHANA RANJEEV | Director | 1 | 2024 | ||
| Pao William | Director | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-07-28 | Immunocore Holdings plc | Biotechnology | $139,999,988 | $139,999,988 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Immunocore Holdings plc | Form D private offerings | CIK (EXACT) | |
| SEC filer | Immunocore Holdings plc | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), X0 first:
- Abcam plc X0
- Autolus Therapeutics plc X0
- Orchard Therapeutics plc X0
- Freeline Therapeutics Holdings plc X0
- Achilles Therapeutics plc X0
- Gyroscope Therapeutics Holdings plc X0
- OKYO Pharma Ltd X0
- Exscientia plc X0
- TC BioPharm (Holdings) plc X0
- BioNTech SE 2M
In other datasets, the same topic (Health) in X0:
- Form D issuer: Abcam plc (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health